Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine

Weitere Versionen anzeigen (1)

Background: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. Adolescents are at particular risk from meningococcal disease, therefore they might benefit from a booster dose of vaccine. The duration of ser...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	De Whalley, P, Snape, MD, Kelly, D, Banner, C, Lewis, S, Diggle, L, John, T, Yu, L, Omar, O, Borkowski, A, Pollard, A
Format:	Journal article
Sprache:	English
Veröffentlicht:	2011

Ähnliche Einträge

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
von: de Whalley, P, et al.
Veröffentlicht: (2011)

Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
von: Snape, MD, et al.
Veröffentlicht: (2006)

Serogroup c meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
von: Snape, M, et al.
Veröffentlicht: (2006)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
von: Snape, MD, et al.
Veröffentlicht: (2009)

Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
von: Micoli, F, et al.
Veröffentlicht: (2013)

Editorial: Glycoconjugates in vaccines and immunotherapeutics
von: Sachin Shivatare, et al.
Veröffentlicht: (2022-08-01)

Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
von: Khatami, A, et al.
Veröffentlicht: (2011)

Towards an improved serogroup B Neisseria meningitidis vaccine.
von: Perrett, K, et al.
Veröffentlicht: (2005)

The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.
von: Valerian B Pinto, et al.
Veröffentlicht: (2013-01-01)

A vaccine against serogroup B Neisseria meningitidis: Dealing with uncertainty
von: Andrews, S, et al.
Veröffentlicht: (2014)

A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty.
von: Andrews, S, et al.
Veröffentlicht: (2014)

Recent advances in lipopolysaccharide-based glycoconjugate vaccines
von: Zhu, H, et al.
Veröffentlicht: (2021)

Impact and Control of Sugar Size in Glycoconjugate Vaccines
von: Giuseppe Stefanetti, et al.
Veröffentlicht: (2022-09-01)

Carriers and Antigens: New Developments in Glycoconjugate Vaccines
von: Robert M.F. van der Put, et al.
Veröffentlicht: (2023-01-01)

Glycoconjugate vaccines against antimicrobial resistant pathogens
von: Charlotte Sorieul, et al.
Veröffentlicht: (2023-12-01)

Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development
von: Cinzia Colombo, et al.
Veröffentlicht: (2018-07-01)

Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness
von: Ray Borrow, et al.
Veröffentlicht: (2023-12-01)

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
von: Perrett, K, et al.
Veröffentlicht: (2009)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
von: Pace, D, et al.
Veröffentlicht: (2016)

Recombinant production platform for Group A Streptococcus glycoconjugate vaccines
von: Sowmya Ajay Castro, et al.
Veröffentlicht: (2025-01-01)

Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.
von: Sara Tartof, et al.
Veröffentlicht: (2013-01-01)

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
von: Snape, MD, et al.
Veröffentlicht: (2008)

Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
von: Khatami, A, et al.
Veröffentlicht: (2012)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
von: Snape, MD, et al.
Veröffentlicht: (2013)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
von: Snape, M, et al.
Veröffentlicht: (2013)

Progress towards a glycoconjugate vaccine against Group A Streptococcus
von: Keira Burns, et al.
Veröffentlicht: (2023-03-01)

Correction: Identifying Optimal Vaccination Strategies for Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt.
von: Sara Tartof, et al.
Veröffentlicht: (2017-01-01)

Will booster doses be required for serogroup B meningococcal vaccine?
von: McQuaid, F, et al.
Veröffentlicht: (2014)

Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab
von: Meltem Polat, et al.
Veröffentlicht: (2018-11-01)

A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial
von: Pace, D, et al.
Veröffentlicht: (2008)

A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
von: Pace, D, et al.
Veröffentlicht: (2008)

Recent advances in the biosynthesis of polysaccharide-based antimicrobial glycoconjugate vaccines
von: Yuhui Wang, et al.
Veröffentlicht: (2025-01-01)

Conjugation Mechanism for Pneumococcal Glycoconjugate Vaccines: Classic and Emerging Methods
von: Victor Morais, et al.
Veröffentlicht: (2022-12-01)

Site-Specific Conjugation for Fully Controlled Glycoconjugate Vaccine Preparation
von: Aline Pillot, et al.
Veröffentlicht: (2019-11-01)

Improving Chicken Responses to Glycoconjugate Vaccination Against Campylobacter jejuni
von: Harald Nothaft, et al.
Veröffentlicht: (2021-11-01)

Serogroup A Neisseria meningitidis with Reduced Susceptibility to Ciprofloxacin
von: Jacob Strahilevitz, et al.
Veröffentlicht: (2008-10-01)

Neisseria meningitidis Strain of Unknown Serogroup, China
von: Haijian Zhou, et al.
Veröffentlicht: (2011-03-01)

Neisseria meningitidis Serogroup W135, China
von: Zhujun Shao, et al.
Veröffentlicht: (2010-02-01)

Recent developments in glycoconjugates
von: Davis, B
Veröffentlicht: (1999)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
von: Read, R, et al.
Veröffentlicht: (2014)